James Frederick is a practicing Physician Associate (PA-C, MMSc) who studied at Yale University. He also has a bachelor’s degree in creative writing and English Literature from the University of Colorado. He specializes in writing medical content that is approachable, readable and enjoyable. He has a strong background in research, physiology, pharmacotherapy, emergency medicine and critical care medicine. In his free time, he enjoys spending time camping and traveling with his wife and dog.
The U.S. Food and Drug Administration (FDA) announced approval of Tafinlar (dabrafenib) and Mekinist (trametinib) to be delivered in combination for the treatment of patients with metastatic non-small cell lung cancer ... Read more
AstraZeneca has announced that Tagrisso (osimertinib), a medication that’s been in development for the treatment of non-small cell lung cancer (NSCLC), recently received full approval from the U.S. Food and ... Read more